Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to look at effects, good or bad, of combining two
investigational anti-cancer drugs called MPDL3280A and CDX-1401. CDX-1401 is given in
combination with a third agent, poly-ICLC, which is another investigational drug that is
believed to work together with CDX-1401. All investigational drugs, MPDL3280A and CDX-1401 in
conjunction with poly-ICLC, have been evaluated separately in prior studies; however, this is
the first study assessing the combination therapy.